Swedish biotech firm Anocca secured $46 million to support clinical development of VIDAR-1, a nonviral genome-edited T-cell receptor (TCR) T-cell therapy targeting mutant KRAS in pancreatic ductal adenocarcinoma. This Phase I trial, now enrolling across multiple European centers, represents a leading effort to overcome pancreatic cancer’s resistance to treatment. The funding will also facilitate progression of Anocca's pipeline, emphasizing rapid discovery of tumor-selective targets for precision cell therapies in oncology.